Lipoprotein(a) in clinical practice: A guide for the clinician

Authors

Chayakrit Krittanawong, NYU School of Medicine, United States
Neil Sagar Maitra, Scripps Clinic, United States
Adham H. El-Sherbini, Queen's University, Canada
Nishant Shah, Duke University, United States
Carl J. Lavie, John Ochsner Heart and Vascular Institute, United States
Michael D. Shapiro, Wake Forest University School of Medicine, United States
Salim S. Virani, Aga Khan UniversityFollow

Document Type

Article

Department

Office of the Provost; Community Health Sciences

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide. Serum lipoprotein(a) (Lp(a)) has been shown to be an independent and causative risk factor for atherosclerotic CVD and calcific aortic valvular disease. Lp(a) continues to be studied, with emerging insights into the epidemiology of CVD with respect to Lp(a), pathogenic mechanisms of Lp(a) and strategies to mitigate disease. There have been novel insights into genetic polymorphisms of the LPA gene, interactions between concomitant risk factors and Lp(a) based on real-world data, and metabolic pathway targets for Lp(a) reduction. This review highlights these recent advances in our understanding of Lp(a) and discusses management strategies as recommended by cardiovascular professional societies, emerging therapies for lowering Lp(a), and future directions in targeting Lp(a) to reduce CVD.

Comments

Volume, issue, and pagination are not provided by the author/publisher.

Publication (Name of Journal)

Progress in Cardiovascular Diseases

Recommended Citation

Krittanawong, C., Maitra, N. S., El-Sherbini, A. H., Shah, N., Lavie, C. J., Shapiro, M. D., Virani, S. S. (2023). Lipoprotein(a) in clinical practice: A guide for the clinician. Progress in Cardiovascular Diseases.
Available at: https://ecommons.aku.edu/provost_office/476